Approved Drug Shows Promise in Follicular Lymphoma
  (6/6/22)
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report. More >

FDA Approval of Drug Could Be on the Way
  (6/3/22)
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection. More >

Bristol Myers to Buy Precision Oncology Co.
Source: Streetwise Reports  (6/3/22)
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share. More >

Precision Oncology Co. Signs $1.325B Licensing Deal
Source: Streetwise Reports  (6/2/22)
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved. More >

Important Data for COVID Drug Candidate Due This Month
  (6/2/22)
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report. More >

Cancer Patients Have Partial Response With Drug
  (5/28/22)
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report. More >

Cancer Targeting Drug Better Tolerated Than Others
  (5/27/22)
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report. More >

50% Revenue Growth Expected This Year for Biopharma Co.
  (5/26/22)
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report. More >

Target Price on Drug Co. Suggests Possible Huge Returns
  (5/25/22)
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report. More >

US Biopharma Co. Chooses One Endpoint for Phase 3 Trial
Source: Dr. Thomas Shrader  (5/24/22)
With this strategic decision, the company hopes to increase the chances its dry eye disease drug gets greenlighted, noted a BTIG report. More >

Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Source: Streetwise Reports  (5/23/22)
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share. More >

H2/22 Slated to Be Catalyst Rich for Pharma Co.
  (5/21/22)
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs. More >

US Pharma Co. Granted FDA Approval for IV Smallpox Drug
Source: Streetwise Reports  (5/20/22)
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox. More >

New Improved Drug Expected to Get FDA Approval Next Month
  (5/20/22)
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock. More >

Firm Reports Encouraging Trial Results in Cystinosis
  (5/19/22)
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc. More >

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox
Source: Streetwise Reports  (5/19/22)
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox. More >

Coverage Launched on Co. in Alzheimer's Drug Space
  (5/17/22)
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report. More >

Clinical Catalysts for Biotech's Stock On Track for Mid 2022
  (5/15/22)
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report. More >

Biopharma Co. to Launch Two Clinical Trials This Year
  (5/14/22)
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report. More >

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Source: Streetwise Reports  (5/13/22)
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development, and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer. More >

First Results From Biotech Co.'s Lymphoma Program Are Impressive
  (5/13/22)
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report. More >

Pfizer Offers $11.6B to Buy Biopharma Co.
Source: Streetwise Reports  (5/10/22)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities. More >

Analyst Says Avivagen Is a Strong Buy
Source: Clive Maund  (5/5/22)
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy. More >

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Source: Streetwise Reports  (5/5/22)
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver. More >

Pilot Launch of VLN Cigarettes in Progress
  (5/3/22)
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report. More >